Michael A Jensen

US Patent:

20080131415, Jun 5, 2008

Filed:

Oct 11, 2007

Appl. No.:

11/870776

Inventors:

Stanley R. Riddell - Sammamish WA, US
Carolina Berger - Seattle WA, US
Michael C. Jensen - Sierra Madre CA, US

International Classification:

A61K 35/00
C12N 5/06

US Classification:

424 9371, 4353723

Abstract:

The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

US Patent:

20120301447, Nov 29, 2012

Filed:

May 3, 2012

Appl. No.:

13/463247

Inventors:

Michael C. Jensen - Bainbridge Island WA, US

International Classification:

A61K 35/14
A61P 35/00
C12N 5/10
C12N 15/12

US Classification:

424 9321, 536 235, 4353723

Abstract:

A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.

US Patent:

20220372140, Nov 24, 2022

Filed:

Apr 21, 2022

Appl. No.:

17/660114

Inventors:

- Seattle WA, US
Michael C. Jensen - Bainbridge Island WA, US

International Classification:

C07K 16/28
A61K 35/17
C12N 5/0783
C07K 14/725
C07K 14/705
C12N 15/85
A61K 35/28
A61K 38/17
C07K 14/71
C07K 14/715
C07K 16/32
A61K 39/395
C12N 9/12

Abstract:

Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as, peripheral blood or apheresis derived mononuclear cells. Once selected/isolated, the CD4+ and/or CD8+ T-cells are then activated, genetically modified, and propagated, preferably, in separate or isolated cultures in the presence of one or more cytokines, which support survival, engraftment and/or proliferation of the cells, as well as, preferably promoting or inducing the retention of cell surface receptors, such as CD62L, CD28, and/or CD27. Included herein are also methods of treatment, inhibition, amelioration, or elimination of a cancer by administering to a subject in need thereof, one or more types of the genetically engineered T-cells or compositions that comprise the genetically engineered T-cell prepared as described herein.

US Patent:

20220193136, Jun 23, 2022

Filed:

Jan 5, 2022

Appl. No.:

17/569107

Inventors:

- Oakland CA, US
- Seatlle WA, US
Michael C. JENSEN - Seattle WA, US

International Classification:

A61K 35/17
C07K 16/46
C12N 5/0783
C07K 16/28
C07K 14/725
C07K 14/705

Abstract:

A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

US Patent:

20230130938, Apr 27, 2023

Filed:

Sep 12, 2022

Appl. No.:

17/931258

Inventors:

- Seattle WA, US
Michael C. Jensen - Bainbridge Island WA, US

International Classification:

A61K 35/17
A61P 35/00
C07K 14/725
C07K 14/705
C07K 16/30
C07K 16/28

Abstract:

Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.

US Patent:

20230050022, Feb 16, 2023

Filed:

Jul 15, 2022

Appl. No.:

17/813021

Inventors:

- Seattle WA, US
Emmeline Cheng - Seattle WA, US
Ian Cardle - Seattle WA, US
Michael Jensen - Seattle WA, US

Assignee:

University of Washington - Seattle WA
Seattle Children's Hospital d/b/a Seattle Children's Research Institute - Seattle WA

International Classification:

C12N 5/00
C12N 15/115
A61K 47/54
A61K 35/17

Abstract:

Described herein are aptamers that bind to the transferrin receptor (e.g., CD71) and can be used, in part, for depleting transferrin receptor-expressing cells from a population of therapeutic cells. These aptamer compositions can be used in methods for isolating and/or enriching cells expressing CD71 or depleting cell populations of cells expressing CD71, including for example, tumor cells. Further provided are methods of using the aptamers or cell populations generated using them in the methods disclosed herein for therapies and/or drug delivery.

US Patent:

20210371517, Dec 2, 2021

Filed:

Nov 13, 2020

Appl. No.:

17/097630

Inventors:

- Seattle WA, US
Michael C. Jensen - Bainbridge Island WA, US

International Classification:

C07K 16/28
A61K 35/17
C12N 5/0783
C07K 14/725
C07K 14/705
C12N 15/85
A61K 35/28
A61K 38/17
C07K 14/71
C07K 14/715
C07K 16/32
A61K 39/395
C12N 9/12

Abstract:

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.

US Patent:

20210324083, Oct 21, 2021

Filed:

Aug 29, 2019

Appl. No.:

17/271813

Inventors:

- Seattle WA, US
Michael C. Jensen - Seattle WA, US

International Classification:

C07K 16/28
C07K 14/705
C07K 14/725
C07K 14/71

Abstract:

Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.